TEMPERATURE-RESPONSIVE VIRUS STORAGE SYSTEM
A temperature-responsive vims storage system that allows vims to be stored, such as a non-frozen liquid, and maintain infectivity is described.
1 . A composition comprising:
an infective virus and a final buffer made by combining one part (w/w) of a buffer formulation with nine parts (w/w) purified water,
wherein the composition comprises the infective virus suspended therein at a concentration of about 3×10 11 adenoviral particles per mL of buffer; and
wherein the buffer formulation comprises the following components, in an amount (w/w) of each component expressed as a percent of the weight of tromethamine used to make the buffer:
about 6000% glycerol;
about 1200% sucrose;
about 100% tromethamine;
about 100% sodium dihydrogen phosphate dihydrate;
about 590% hydroxypropyl beta-cyclodextrin;
about 21% magnesium chloride hexahydrate;
about 71% (3a,50,7a,12a)—N43-[(4-O-D-galactopyranosyl-D-gluconoyl)amino]propyli-3,7,12-trihydroxy-N43-[[(3a,50,7a,12a)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]propyli-cholan-24-amide (NODA)
about 36% polysorbate 80;
about 3% sodium citrate dihydrate; and
about 1% citric acid monohydrate.
2 . The composition of claim 1 , wherein the infective virus is a lentivirus, adenovirus or adeno-associated virus.
3 . The composition of claim 2 , wherein the infective virus is a replication-deficient adenovirus.
4 . A method of treating a subject suffering from bladder cancer, the method comprising administering to the subject the composition of claim 1 .
5 . The method of claim 4 , wherein the infective virus is a lentivirus, adenovirus or adeno-associated virus.
6 . The method of claim 5 , wherein the infective virus is a replication-deficient adenovirus.
7 . The method of claim 4 , wherein the bladder cancer is Bacillus Calmette-Guerin (BCG)-resistant cancer.